Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Payables (2016 - 2025)

International Stem Cell (ISCO) has disclosed Payables for 16 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 2.94% to $3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.6 million, a 2.94% decrease, with the full-year FY2024 number at $3.6 million, down 6.28% from a year prior.
  • Payables was $3.6 million for Q3 2025 at International Stem Cell, down from $3.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.9 million in Q2 2024 to a low of $3.4 million in Q2 2021.
  • A 5-year average of $3.7 million and a median of $3.7 million in 2024 define the central range for Payables.
  • Peak YoY movement for Payables: soared 858.61% in 2021, then fell 6.28% in 2024.
  • International Stem Cell's Payables stood at $3.5 million in 2021, then increased by 5.68% to $3.6 million in 2022, then rose by 4.77% to $3.8 million in 2023, then fell by 6.28% to $3.6 million in 2024, then fell by 0.31% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Payables are $3.6 million (Q3 2025), $3.7 million (Q2 2025), and $3.9 million (Q1 2025).